Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
[(1S)-4-(1-Aminobutylideneamino)-1-carboxybutyl]azanium is a synthetic small molecule belonging to the class of L-alpha-amino acids. It is structurally related to arginine derivatives and has been studied primarily as an experimental compound. The molecule has been identified as a ligand for nitric oxide synthase 1 (NOS1), also known as neuronal nitric oxide synthase, suggesting it may act by interacting with this enzyme, which plays a key role in the production of nitric oxide from L-arginine in neural tissues[2][3]. There are no approved therapeutic indications or marketed products containing this compound, and its pharmacological properties remain largely uncharacterized.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on [(1S)-4-(1-aminobutylideneamino)-1-carboxybutyl]azanium.